For decades, neurofibromatosis type 2 (NF2) was misclassified with the more common neurofibromatosis type 1 (NFl), until 1987 when it was found via genetic linkage analysis that the gene for NF 1 was localized to chromosome 17 and the gene for NF2 was localized to chromosome 22.
Introduction
Type 2 neurofibromatosis (NF2) was probably first described by Wishart in 1820. 1 However, after von Recklinghausen reported cases of type 1 neurofibromatosis (NF1),2 various reports ofNF2 cases around the turn of the century were incorrectly categorized with von Recklinghausen's disease. Probably the most to blame for the prolonged co-classification of NFl and NF2 was Cushing.' Although many reports emphasized the lack of skin tumors or cafe au lait skin patches in patients and families with bilateral vestibular schwannomas.r" the final separation of NFl and NF2 and their delineation only came in 1987. In that year the gene for NFl was localized to chromosome 17 and the gene for NF2 to chromosome 22 7 by genetic linkage analysis. As a result of this and the increasing clinical evidence to implicate two distinct disorders," the National Institutes of Health consensus statement published the following year? for-mally separated them. The still widely held belief that vestibular schwannomas (VS) occur as part of NFl has now been refuted by large, population-based studies of the more common type-I disease. 10 Previous reports of VS in NFl were clearly contaminated with NF2 cases."
NF2 is a dominantly inherited disorder that predisposes affected individuals to the development of vestibular schwannomas (usually bilateral); schwannomas of the other cranial, spinal and peripheral nerves; meningiomas, both intracranial (including those located on the optic nerve) and intraspinal; and some low-grade central nervous system (CNS) malignancies (ependymomas, gliomas).
Three large clinical studies have now confirmed the clinical picture of NF2. 8,12.13 Our own published diagnostic criteria" are shown in Table 1 . The original NIH criteria have been expanded to include patients with no family history who have multiple schwannomas and/or meningiomas, but who have not yet developed bilateral eighth-nerve tumors. Individuals might exhibit cranial meningiomas or a spinal tumor long before the appearance of a vestibular schwannoma. Since at least 50% of cases represent new dominant mutations, 15 our criteria are more inclusive but are still extremely unlikely to include chance associations. The features ofNF2 seen in the three major clinical studies 8, 12 .13 are shown in Table 2 .
Epidemiology
NF2 affects approximately 1 in 35 to 40,000 peop 1e. 15 However, because many patients do not exhibit features of the condition until the third decade or later and many other patients die before this time, the actual diagnostic prevalence is only 1 in 200, 000 Th e bes t exami nation today, in terms of d iag nostic precision , is magn eti c resonance imaging (M RI) with gado linium enha nce ment, which also sho uld includ e a compl ete spinal and cran ial sca n. A ca reful skin and eye examination, ho wever , is also of grea t di agn ostic importan ce. It is now also possible to make a presymptom atic DNA diagnosis (see bel ow).
Genetics
Many studies have confirmed the autosoma l dom inant inheri tance of NF 2, with 50 % of the offspring of an affected ind ividu al also being affec ted. The ge ne has a high degree of penetran ce as ev ide nced by the fac t that it is nearl y alwa ys expressed by the late fifti es.P'The init ial clu e to the whe rea bo uts of the ge ne ca me with the discovery of chro moso me-22 abn ormalities on cyt ogenetic analysis of meningiomas." Th is was confirme d at the molecular level in several different tum ors fro m an NF2 patient , by show ing loss of co nstitutional het erozygosity for chromosom e 22q marker s, prov iding stro ng ev idence that the NF2 ge ne wa s a tumor suppressor, with both co pies of the ge ne needin g to be ina ctivated before init iating tum orige nes is. Thi s fulfi lled the class ic " two -hit" hypothesis of tum origenesis put forward by Knudson in 1971. Asi de fro m retinoblas to ma, for which this hyp oth esis was made, ingiom a or spinal tum or. Occasionally, a sk in tum or will have been removed in chi ldhood, which might have led to a mistaken di agno sis of NF I. Onl y approx ima tely I to 2% ofNF2 patient s fulfill the diagno stic criteria for NF I,9 and even the se can be excluded after ca reful consi deration. No con vincin g reports ex ist to sugg est that a mi xed for m of neurofibrom atosis trul y exis ts. Ch ildh ood ca tarac ts are also co mmon and can prob abl y be found in >2 0% of patient s with NF 2 before the presence of any tum or is detect ed . 12 Cataracts on their ow n are unl ikel y to alert a cli nician to the diagnosis, but in the presence of a family history of NF2 or in a yo ung patient wit h bilateral dea fness or a un ilat eral vestibular schwa nnoma, the pres- • Individuals with a family history of NF 2 • Pati ent s und er 30 years of age with a un ilateral ves tibular schwannom a or meningiom a 2 sprays per nostril twice daily. In placebo-controlledefficacy trials, the incidence of discontinu ation dueto adverse reactions in patients receivingAstelin' Nasal Spraywasnot signilicantly differen t from vehicle placebo (2.2% vs 2.8%, respectivel y).
In these clinical studies, adverse events that occurred statisticaiiysignilicantly more often in patients treated with Astelln" Nasal Spray versus vehicle placebo included bitter taste (19.7% vs 0.6%).somnolence(11.5%vs 5.4%), weight increase (2.0%vs 0%), and myalgia (1.5% vs 0%).
Thefollowing adverse events were repo rted with lrequencies~2' 10 in the Aste lln" Nasal Spray treatment group and more frequentl y thanplacebo in short-term ($2 days) and long-term (2-8 weeks) clinical trials.
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Respiratory: bronchospasm, coughing, throat burning, laryngitis. Special Senses: conjunctivitis, eye abnormality, eye pain, watery eyes, taste loss. Urogenital: albuminuria,amenorrhea, breast pai n, hematuria, increased urinary frequency. Whole Body: allergicreaction, back pain, herpes simplex, viral inlection, malaise, pain in extremities, abdominal pain.
In controlledtrials involvingnasal and oral azelastine hydrochl oride formul ations. there were inlrequent occurrences of hepatic transamin ase elevations.The clinical relevance of these reports has not been established.
In addi tion, the lollowing spontaneous adverseevents have beenreported during the marketing of Astelin' Nasal Sprayand may have no causal relationship with the drug: anaphylactoid reaction, application site reaction, chest pain, condi tion aggravated,confusion , diarrhea, dyspnea, facial edema, involuntary muscle contractions, paresthesia, parosmia,pruritus, rash, tolerance, urinary retention, vision abnormal, and xerophthalmia. OVEROOSAGE There have beenno reported overdosageswith Astelin' Nasal Spray. Acute over dosageby adults with this dosage form is unlikel y to result in clinically significant adverse events, other thanincreased somnolence, sinceone bottle 01Aste lin" Nasal Spraycontains 17 mg of azelasti ne hydrochloride. Clinical studiesin adults with single doses of the oral formulation 01azelastinehydrochloride (up to 16 mg) have not resulted in increasedincidence of seriousadverse events. General supportivemeasures should be employed if overdosage occurs. Thereis no known antidote to Aste lin" Nasal Spray. Oral ingeslion of antihistamineshas the potentiai to causeserious adverse effects in young children. Accordingly, Astelin' Nasal Spray should bekept out of the reac h 01children. Oral doses grea ter than 120 mg/kg (480 timesthe maximumrecom mended human daily intranasal dose on a mg/m' basis) produced signilicant mortality in mice. Responses seen prior to mortality were tremor, convulsions, decreased muscle tone, and salivation. Singledoses as high as 10 mg/kg (270 times the maximum recommend ed human dai ly intranasal dose on a mg/m' basis) were welltolerated in dogs, but single doses of 20 mg/kg were lethal. DOSAGE AND ADMINISTRATIDN The recommended dose of Astelin' Nasal Sprayin adults and children 12 years and older is two sprays per nostril twice daily. Before initial use, the screwcap on the bottle should be replacedwith thepump unit and the deliverysystem should be primedwith 4 sprays or until a fine mist appears. When 3 or moredays have elapsed since the last use, the pumpshould be reprimed with 2 sprays or until a fine mist appears. CAUTION, Avoid spraying in the eyes. Directions lor Use: Illustrated patient instructions for properuse accompanyeach package of Astelin' Nasal Spray. HOW SUPPLIED Astelin" (azelasti nehydrochloride) Nasal Spray, 137 mcg (NDC 0037-0241-10) is supplied asa package containing a total of 200metered sprays in two high-density polyethylene (HDPE)bottlesfittedwith screwcaps. A separate metered -dose spraypump unit and a leaflet of patient instructions are also provided. The spray pump unit is packaged in a polyethylenewrapperand consists of a nasal spray pump fittedwith a bluesafety clip and a blueplastic dust cover.
Each Aste lin" (azelastinehydrochloride) Nasal Spray, 137 mcg, bottle contai ns 17 mg (1 mg/mL) of azelastinehydrochloride to be usedwith the supplied metered-dose spraypump unit. Each bottle candeliver 100 metered sprays. Each spraydeliversa mean of 0.137 mL solution containing 137 mcg of aze lastinehydrochloride.
The following events were observed inlrequently «2% and excee ding placebo incidence) in patients who rece ived Astelln" Nasal Spray(2 sprays/nostril twice daily) in U. S Patients should be advised against the concurrent use of Astelin' Nasal Spraywith other antihistamines without consulting a physician. Patients who are, or may become, pregnant should be told that this product should be used in pregnancy or during lactation only if the potential benefit justifies the potential risks to the fetus or nursing infant.Pa tients should be advised to assess their indi vidual responses to Astelin" Nasal Spraybeforeengaging in anyactivity requiring mental alertness, such as driving a car or operating machi nery. Patient s should beadvised that theconcu rrentuse of Astelin' Nasal Spraywith alcohol or otherCNSdepressants may lead to additional reductions in alertness and impairment of CNSperformance and should beavoided (see Drug Interactions). Orog Interactions: Concurrent use of Astelin" Nasal Spraywith alcohol or other CNSdepressants should be avoided because additional redu ctions in alertness and additional impairment of CNS performance may occur.
Ci metidine(400 mg twice daily) increased themeanCmaxand AUC 01orally administered azelastine hydrochloride (4 mg twicedaily) by approxi mately 6S% . Ranitidine hydrochl oride (150 mg twice daily) hadno effect on azelastinepharmacokin etics.
Interaction studiesinvestigating the cardiaceffects, asmeasured by the corrected aT interval (OTc). of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. Oral eryt hromycin (500 mg three timesdaily for seven days) hadno effect on azelastine pharmacokinetics or OTcbased on analyses of serial electrocardiograms. Ketoconazole (200 mg twice daily for 7 days) interfered with the measurement of azelast ine plasma concentrations; however, no effects on OTcwere observed. No significant pharmacokinetic interaction was observed with the coadministration of an oral 4 mg dose of aze lastine hydrochloride twice dail y and theophyiiine 300 mg or 400 mg twice daily. Geriatric Use: U.S. placebo-controlledclinical trials included 11 patient s above the age of 60 yea rs who were treated with Astelin' Nasal Spray. While thi s numberis verysmall and no substantial conclusions can be drawn, the adverse events in this groupwere similar to patients under age60 yea rs. Carcinogenesis, Mutagenesis, Impairment 01Fertility: Carcinogenicity studiesin rats and mice with oral azelastinehydrochloride for 24 months at doses up to 30 mg/kg/day and 25 mg/kg/day, respectively (240 and 100 times themaximum recommended human daily intranasal dose on a mg/m' basis), revealed no evi denceof carcinogenicity.
Aze lastinehydrochloride showed no genotoxic effectsin the Amestest, DNA repair test, mouse lymphoma forward mutation assay, mouse micronu cleus test, or chromosomal aberration test in rat bonemarrow.
Reproduction and fertility studiesin rats showed no effects on male or female fertility at oral doses of up to 30 mg/kg/day (240 times themaximum reco mmended humandai ly intranasal dose on a mg/m' basis). At 68.6mg/kg/day (550 timesthe maximum recommend edhuman daily intranasal dose on a mg/m' basis), the duration 01estrous cycleswasprolonged and copulatory activity and the number of preg nancieswere decreased. The numbers of corpora lutea and implantat ions were decreased; however, the implant ation ratio wasnot affected. PregnancyCa tegory C: Aze lastinehydrochloride has been shown to be ernbryotoxic, fetotoxic, and teratogeni c (external and skeletal abnormalities)in miceat an oral dose of 68.6 mg/kg/day (280 times the maximum recommendedhumandaily intranasal dose on a mg/m' basis).
At an oral dose of 30 mg/kg/day (240 timesthe maximum recommended humandaily intranasal dose on a mg/m' basis), delayed ossi licat ion (undeveloped metacarpus), and the incidenceof 14th rib were increased in rats. At 68.6mg/kg/day (550 times the maximumrecommended human daily intranasal dose on a mg/m' basi s) azelastinehydrochloride caused abortion and fetotoxic effects in rats.
The rel evance to humans of these skeletal findings noted at only highdrug exposurelevels is unknown.
There areno adequate and well-controlledclinical studiesin pregnant women. Astelin? Nasal Spray should be usedduring pregnancyonly if the potential benefit justifiesthe potential risk to the letus. Nursing Mothers: It is not known whet her azelastinehydrochloride is excreted in human milk. Becausemany drugs areexcretedin human milk, caution should beexercise d when Astelin" Nasal Sprayis administered to a nursing woman. PediatricUse: Safetyand efficacy 01Astelin" Nasal Sprayin pediatric patients below the age of 12 years have not been established. AOVERSE REACTIONS Adverse experience inlormationlor Astelin" Nasal Spray is deri vedIrom six well-controlled, 2-dayto 8-week clinical studieswhich included391 patients who rece ived Astelin" Nasal Sprayat a dose of 
Loratadine plus beclomethasone
The most commonly reported adverse events were bitter taste, somnolence, and rhinitis.
*Physician global evaluation of patients' need for additional therapy at end of study.
"There were no statistically significant differences between treatment groups in study 1 and 2; there was a statistically significant difference between treatment groups in study 3 (P=O.04) .
Please see accompanying brief summary of prescribing information on first page of advertisement.~n NF2 is perha ps the best example of this mec han ism. Every Sch wann ce ll in NF2 alrea dy carries a mut ant co py of the gene, and if the othe r co py is mu tated or de leted , a tumo r ensues. Little evi de nce supports the invo lvement of other ge nes in the formation of schwannomas .
After confirming a site of tumor loss, linkage studies then confirmed that all affected members of the large Pennsylvania family first reported in 1930 4 carrie d the same co py of chro mosome 22. 7 Further studies have shown a lack of evidence for another gene to acco unt for the NF2 phenotype and that this is almost certai nly caused by a single gene on 22q.19The NF2 gene was further localized by the discovery of germline deletion s in NF2 families, one of which invo lved the neurofilam ent heavy-chain gene." Th e ge ne itself was eve ntually isolate d by the discovery of co nstitutional and tum or deletions in a cell-me mbrane-related ge ne ca lled "merlin'? ' or "sc hwannornin.?" Several studies have now co nfirme d thi s locus as the NF2 ge ne. Standar d mut ation techn iques, such as si nglestrand co nfirma tio nal po lymo rphism (SSCP) or den aturing gr adie nt ge l elec trophoresis (DGGE), detect between 35 and 60 % of ca usa tive mutati ons.P'" Most of these mut ati on s are trunca ting mut ation s, leadi ng to a sma ller and prob abl y ineffective protei n produ ct. Th is means that more rapid scree ning techn iqu es, such as the protein trun cat ion tes t (PT T), co uld be em ployed. T here are now indications of a ge noty pe/phenotype corre latio n with most missense mut ation s, which will give rise to a complete protein product , or delet ions that give no prote in pro duct produ cin g a mild phenotype. 20 .23.26.29 Th e more severe phenotyp e with truncating mu tations might be caused by a dominant negative effec t, with mut ant protein dim er izing with the norma l product , leaving less wild-t ype protein fo r tum or suppression. Som e evi de nce also indicates that mild er cases might represent mosaic d isease,")with only a pro por tion of ce lls con tain ing the mut ated NF 2 ge ne (mutation occ urred after concepti on).
Pred icti ve diagnosis by linkage analysis , using markers flanking the NF 2 ge ne, is now possible in the vas t majority of families with two or more living affec ted indi viduals. 19 . 26 ,31 Onc e a mut ation has been identified in an affected indi vidu al, a 100% spec ific test is ava ilable for that person ' s family. Mutation detec tion is tim e co nsu ming and expensive, however, and might not reveal the causa tive mutation . In most fam ilies with more than one affected individual, linkage analysis will still remain the test of choi ce because it will give >99 % cer tainty when intrage nic or flan king markers are used . By co mbining thi s analysis with a curve for cumulative age at onse t (Fig ure) the risk to an unaffected 30-yea r-o ld with a normal MRI sca n and favorable DNA result wo uld be infinitesimally sma ll. One hundred percent co nfide nce ca n still only be atta ined with the identification of family-spec ific mut ations.
Recent ev ide nce suggests tha t patient s wi th what has previou sly been describ ed as schwa nnoma tosis actua lly Volume 78, Number 2 have a variant for m of NF2. In this co ndition, the tumo rs are largely co nfi ned to the skin and spi ne, with spari ng of the eig hth nerve. Mutations in the NF2 ge ne are now being found in pat ient s with this variant fo rm of the disease." Therefore, at an allelic level , vestibular schwa nno mas shou ld not be conside red as an inevit abl e con sequ en ce of NF2 disease-causing mut ation s.
Modifying Factors
So me evidence suggests tha t NF2 might be worse if the disease is inher ited from the mother.v" However, th is co uld also result fro m decreased ge netic fitness in men , with only the less severely affected men having offspring . As there is no evidence for ge nomic imprinti ng on chromosom e 22 q, the previous rep orts of a maternal ge ne effec t might be spurio us. Som e ev ide nce also supports a ge nera l worsening of the di sease with successive ge neration s," so ca lled "anticipation." No objective evidence co nfirms thi s, however. Th ere has also been a stro ngly held belief that the disease co urse is worse in affected females. " A more co mplete analysis , however, wo uld suggest that the effect is mainly on meni ngioma rat her than schwanno ma growth and de vel opment. P On the who le, the NF 2 disease co urse does breed true in families. So me families have a mild di sease course with late onset and few, if any, CNS tumor s othe r than vest ibular schwanno mas . Oth er fa milies have a more viru lent co urse, w ith early o nset a nd death res ulting from multitumor disease. Th e early ev ide nce of a genotype/ phen otype correlation is encourag ing and might we ll add insig ht into the disease process . Non eth eless, much wi ll depend on stoc has tic events, such as loss of the second NF2 alle le, because the disease co urse, even in monozygo tic twin s, is not ide ntica l."
The Future
T he much-awaited step in NF2 was the localization and cloning of the ge ne. Thi s achieve d, precise diagnosis is EVANS now possible if a speci fic mutation can be found , but thi s might also allo w prediction of disease course by genotype/phenotype studies. Thi s will not be as imp ortant in families where we already know the extent of the disease, but in new mutations in whom an insight into the likel y speed of tum or progression and risk of other tumors would be helpful. Alth ough DNA predi ctiv e testin g is now available with flankin g markers, there is currently little demand for prenatal diagno ses. A less controversial option would be preimplantatio n diagno sis, which is being evalu ated in a limited sense for other diseases, such as familial adenomatous polyposis and cystic fibrosis.
The real hope is that the disco very of the gene and its transcriptional protein product , merlin/schw annomin, will lead to the development of somatic ge ne therapy. Instinctively, the pro spe cts for NF2 app ear promi sing. Thi s is because of the lack of variation in individuals with the same mutation and becau se of the paucity of invol vement of other genes in the tumo rs them selves. Replacement of the tumor-suppressor produ ct in the tum ors through viral vectors or direct recombination of the NF2 gene, although requiring great advances in our knowledge, could be extremel y rewarding.
